Can Pan-TRK Immunohistochemistry Identify NTRK Fusions in Lung Cancer?

Description

A retrospective analysis published in Scientific Reports examined the use of immunohistochemistry with the pan-TRK antibody to detect NTRK fusions in non–small cell lung carcinoma. Luka Brcic, PhD, and colleagues from the Diagnostic and Research Institute of Pathology, Medical University of Graz, Austria, reported that pan-TRK expression in lung cancers is very low across histologic types, and confirmation of immunohistochemistry results should be validated using molecular methods.